

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Dyddiad/Date: 14th September 2021 Ein Cyf / Our Ref: 21-H-033

01639 648363

FOIA.Requests@wales.nhs.uk
Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

I refer to your Freedom of Information Act Request acknowledged by ourselves on 25th August 2021. Your request sought information relating to Schizophrenia treatment.

We have provided this information for the period 01.01.21 to 30.06.21.

1. In the past 6 months, how many patients has your Health Board treated [for any condition] with the following drugs:

Please note that we are only able to provide patient numbers for Secondary Care unless indicated otherwise. Numbers provided for Primary Care are numbers dispensed as prescriptions rather than patient numbers.

Secondary Care

- Aripiprazole long-acting injectable (Abilify Maintena) 114
- Olanzapine pamoate (Zypadhera) <5*
- Paliperidone palmitate, once monthly (Xeplion) 99
- Paliperidone palmitate, three monthly (Trevicta) 17
- Risperidone long-acting injectable (Risperdal Consta) 77 (Issued as stock to ward areas – unable to provide accurate patient numbers from Pharmacy stock control system)
- Flupentixol decanoate (Depixol) 51 (Issued as stock to ward areas unable to provide accurate patient numbers from Pharmacy stock control system)
- Fluphenazine decanoate (Modecate) 0



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- Haloperidol decanoate (Haldol Decanoate) 8 (Issued as stock to ward areas unable to provide accurate patient numbers from Pharmacy stock control system)
- Pipotiazine palmitate (Piportil) 0
- Zuclopenthixol decanoate (Clopixol) 36 (Issued as stock to ward areas unable to provide accurate patient numbers from Pharmacy stock control system)

Primary Care

- Aripiprazole long-acting injectable (Abilify Maintena) 0
- Olanzapine pamoate (Zypadhera) 0
- Paliperidone palmitate, once monthly (Xeplion) 0
- Paliperidone palmitate, three monthly (Trevicta) 0
- Risperidone long-acting injectable (Risperdal Consta) 0
- Flupentixol decanoate (Depixol) <5*
- Fluphenazine decanoate (Modecate) 0
- Haloperidol decanoate (Haldol Decanoate) <5*
- Pipotiazine palmitate (Piportil) 0
- Zuclopenthixol decanoate (Clopixol) 0

2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)

The numbers in the table below does not include patients treated in the community mental health teams – ICD10 coding is not recorded in the community.

Number treated in outpatients	430
Number treated as inpatients	90

3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:

- Aripiprazole long-acting injectable (Abilify Maintena) 46
- Olanzapine pamoate (Zypadhera) <5*
- Paliperidone palmitate, once monthly (Xeplion) 45
- Paliperidone palmitate, three monthly (Trevicta) <5*
- Risperidone long-acting injectable (Risperdal Consta) 36
- Flupentixol decanoate (Depixol) 104
- Fluphenazine decanoate (Modecate) 0
- Haloperidol decanoate (Haldol Decanoate) 6
- Pipotiazine palmitate (Piportil) 0
- Zuclopenthixol decanoate (Clopixol) 59

* Where fewer than 5 has been indicated we are unable to provide you with the exact number as due to the low numbers, there is a potential risk of identifying individuals

if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at <u>FOIA.Requests@wales.nhs.uk</u>.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via <u>FOIA.Requests@wales.nhs.uk</u>.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely

P. a. wenje

Pam Wenger Director of Corporate Governance